Solvac financials
Solvac
549300EO33NRZ1PZRW58 | Line item | 2022 | 2021 |
|---|---|---|
| Income statement | ||
| Operating expenses | €2.0M | €2.0M |
| Profit for the year | €594.0M | €293.0M |
| Total comprehensive income | €734.0M | €611.0M |
| Per share | ||
| Basic EPS | €27.80 | €13.70 |
| Diluted EPS | €27.80 | €13.70 |
| Cash flow statement | ||
| Net cash from operating activities | €125.0M | €120.0M |
| Net cash from investing activities | €0 | €0 |
| Net cash from financing activities | -€124.0M | -€120.0M |
| Dividends paid | €119.0M | €116.0M |
| Proceeds from borrowings | €48.0M | €50.0M |
| Repayments of borrowings | €50.0M | €51.0M |
| Balance sheet | ||
| Total assets | €3.73B | — |
| Property, plant & equipment | €0 | — |
| Intangible assets & goodwill | €343.0M | — |
| Trade & other receivables | €50.0M | — |
| Cash & equivalents | €1.0M | €0 |
| Total equity | €3.51B | €2.93B |
| Long-term borrowings | €150.0M | — |
| Current liabilities | €66.0M | — |
| Short-term borrowings | €48.0M | — |
| Derived metrics | ||
| Return on equity | 16.9% | 10.0% |
| Cash conversion ratio | 0.21× | 0.41× |
| Other reported items | ||
| Adjustments For Interest Expense | €3.0M | €3.0M |
| Adjustments For Undistributed Profits of Investments Accounted For Using Equity Method | €599.0M | €298.0M |
| Current Tax Liabilities Current | €14.0M | — |
| Dividends Received Classified As Operating Activities | €125.0M | €122.0M |
| Dividends Recognised As Distributions To Owners Per Share | €5.58 | — |
| Equity and Liabilities | €3.73B | — |
| Gains Losses On Cash Flow Hedges Before Tax | €25.0M | -€5.0M |
| Income Tax Relating To Components of Other Comprehensive Income | €21.0M | €24.0M |
| Increase Decrease In Cash and Cash Equivalents | €1.0M | €0 |
| Increase Decrease In Working Capital | -€2.0M | €0 |
| Increase Decrease Through Transfers and Other Changes Equity | -€30.0M | -€19.0M |
| Increase Decrease Through Treasury Share Transactions | €0 | €0 |
| Interest Expense | €3.0M | €3.0M |
| Interest Paid Classified As Financing Activities | €3.0M | €3.0M |
| Investment Accounted For Using Equity Method | €3.33B | — |
| Issued Capital | €192.0M | — |
| Other Comprehensive Income | €140.0M | €318.0M |
| Other Comprehensive Income Before Tax Exchange Differences On Translation | €96.0M | €160.0M |
| Other Comprehensive Income Before Tax Gains Losses From Investments In Equity Instruments | -€8.0M | €10.0M |
| Other Comprehensive Income Before Tax Gains Losses On Remeasurements of Defined Benefit Plans | €48.0M | €177.0M |
| Other Current Liabilities | €4.0M | — |
| Payments To Acquire Or Redeem Entitys Shares | €0 | €0 |
| Proceeds From Issuing Shares | €0 | €0 |
| Proceeds From Sales of Investments Accounted For Using Equity Method | €0 | €0 |
| Purchase of Interests In Investments Accounted For Using Equity Method | €0 | €0 |
| Share of Profit Loss of Associates and Joint Ventures Accounted For Using Equity Method | €599.0M | €298.0M |
Every line item above is a fact tagged in Solvac's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.